International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 3, Issue 10 | Case Report | Open Access DOI

Prolactinoma

Praneeth Ulavala^*

Praneeth Ulavala1*, Harichandana Kalangi2 and Sravanthi Narapaneni1

1Narayana Medical College and Hospitals, Nellore, Andhra Pradesh, 524003, India

2Kamineni Academy of Medical Sciences and Research, L. B. Nagar, Hyderabad, Telangana, 500068, India

^*Correspondence to: Praneeth Ulavala 

Abstract

Prolactinomas are benign pituitary tumors characterized by excessive secretion of prolactin. While more common in females, these tumors can also significantly impact male patients, leading to symptoms such as hypogonadism, infertility and gynecomastia. Traditional treatments include dopamine agonists, surgery and in some cases, radiation therapy with varying degrees of success. This article explores the clinical presentation, diagnostic challenges and therapeutic approaches specific to prolactinomas in male patients.

Prolactinomas account for approximately 40% of pituitary adenomas, with their impact on male patients often being underrecognized due to atypical presentations compared to females. These tumors can result in reduced testosterone levels, sexual dysfunction and even osteoporosis due to chronic hypogonadism. The primary treatment modality, dopamine agonists, aims to normalize prolactin levels, shrink tumor size and restore gonadal function. However, resistance to dopamine agonists and side effects remain challenges in management. In such cases, surgical intervention or radiation therapy may be considered.

In conclusion, managing prolactinomas in male patients requires a nuanced approach, considering the distinct clinical presentations and challenges associated with treatment. Early diagnosis and appropriate therapy are critical for preserving quality of life and preventing long-term complications.

Keywords:

Prolactinoma; Male hypogonadism; Dopamine agonists; Pituitary adenoma; Prolactin management

Citation:

Ulavala P, Kalangi H, Narapaneni S. Prolactinoma. Int Clinc Med Case Rep Jour. 2024;3(10):1-5.